Vaxart (VXRT) AI Stock Analysis

• Market Cap: $94.82M
• Dividend Yield: N/A
• Average Volume (3M): 1.89M
• Price to Earnings (P/E): ―
• Beta (1Y): 2.07
• Revenue Growth: 433.43%
• EPS Growth: 49.04%
• Country: US
• Employees: 105
• Sector: Healthcare
• Sector Strength: 38
• Industry: Biotechnology
• EPS (TTM): -0.07
• Shares Outstanding: 228,208,280
• 10 Day Avg. Volume: 1,686,830
• 30 Day Avg. Volume: 1,892,061
• PEG Ratio: -0.11
• Price to Book (P/B): 1.62
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -2.11
• Enterprise Value/Market Cap: 0.93
• Enterprise Value/Revenue: 1.36
• Enterprise Value/Gross Profit: 9.76
• Enterprise Value/Ebitda: -0.34
• 1Y Price Target: $3.00
• Price Target Upside: 614.29% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2

Vaxart's stock score reflects strong revenue growth and progress in clinical trials. However, significant profitability challenges, cash flow management issues, and bearish technical indicators weigh heavily on the stock. The risk of NASDAQ delisting and strategic initiatives such as the reverse stock split are key factors impacting the overall outlook. The company's efforts to stabilize its financial position and improve operational efficiencies will be crucial for future stability.

Positive Factors

Financial Support

Vaxart advances with $453M BARDA-backed COVID-19 vaccine, poised to lead in mucosal immunity.

Regulatory Progress

Management is in ongoing active discussions with the FDA, highlighted by a recent Type C meeting, to clarify potential late-stage development, which could expedite the path to market.

Negative Factors

Market Perception

Investor perception of the norovirus opportunity has considerable room for improvement given the significant disease burden and the lack of approved or late-stage programs.

Vaxart Business Overview & Revenue Model

Company Description

Vaxart, Inc., a clinical-stage biotechnology company, engages in the discovery and development of oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, an oral tablet vaccine, which is in a Phase Ib clinical trial with bivalent oral tablet vaccine for the GI.1 and GII.4 norovirus strains; seasonal influenza vaccine, which is in Phase II clinical trial for the treatment of H1 influenza infection; respiratory syncytial virus vaccine; and coronavirus vaccine, which is in Phase II clinical trial for the treatment of SARS-CoV-2 infection. It is also developing therapeutic vaccines for cervical cancer and dysplasia caused by human papillomavirus. The company is headquartered in South San Francisco, California.

How the Company Makes Money

Vaxart generates revenue primarily through partnerships, collaborations, and licensing agreements with other pharmaceutical and biotechnology companies. These partnerships typically involve upfront payments, milestone payments, and potential royalties on sales of products developed using Vaxart's technology. The company is also engaged in research and development activities that are sometimes funded by government grants or contracts, which provide additional revenue streams. As of now, Vaxart does not have a commercialized product on the market, so its revenue is largely dependent on these partnerships and funding sources.

Vaxart Financial Statement Overview

Summary

Vaxart has demonstrated strong revenue growth, but it continues to struggle with profitability and cash flow management. The balance sheet shows moderate leverage, providing some financial stability, but the negative cash flows highlight ongoing operational challenges. Moving forward, improving operational efficiencies and cash flow management will be crucial for sustainable growth.

Income Statement

Vaxart has shown a significant increase in total revenue in the latest year, from $7.38 million to $28.7 million, reflecting a strong growth trajectory. However, the company continues to face challenges with profitability as indicated by negative net income and EBIT, resulting in negative net profit and EBIT margins. The lack of positive EBITDA also highlights ongoing operational inefficiencies.

Balance Sheet

The balance sheet shows a relatively stable equity position with a stockholders' equity of $58.9 million. However, the company has a high debt-to-equity ratio at 0.30, suggesting that the company is moderately leveraged. The equity ratio is approximately 35.4%, indicating that a significant portion of assets is financed by equity, which provides some financial stability.

Cash Flow

The cash flow statement reveals challenges with negative free cash flow and operating cash flow, which are concerning trends. Despite a significant cash infusion from financing activities, the free cash flow to net income ratio and operating cash flow to net income ratio are negative, reflecting ongoing cash management issues.

Breakdown
Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
28.70M	7.38M	107.00K	892.00K	4.05M
	Gross Profit
24.30M	-60.76M	-3.16M	-47.86M	-15.82M
	EBIT
-66.29M	-83.35M	-114.59M	-72.75M	-30.17M
	EBITDA
-59.32M	-72.13M	-103.12M	-66.45M	-28.26M
	Net Income Common Stockholders
-66.95M	-82.47M	-107.76M	-70.47M	-32.22M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
51.72M	39.71M	93.72M	166.49M	126.87M
	Total Assets
166.39M	91.83M	153.85M	221.17M	152.58M
	Total Debt
17.53M	26.51M	21.70M	13.01M	7.21M
	Net Debt
-7.70M	-8.24M	-22.31M	-130.74M	-119.66M
	Total Liabilities
107.46M	34.02M	43.25M	33.64M	29.18M
	Stockholders Equity
58.92M	57.80M	110.60M	187.53M	123.40M
Cash Flow		Free Cash Flow
-45.32M	-72.32M	-104.38M	-64.99M	-24.97M
	Operating Cash Flow
-44.76M	-70.45M	-94.78M	-59.83M	-23.75M
	Investing Cash Flow
-21.32M	43.95M	-20.41M	-49.10M	-1.22M
	Financing Cash Flow
56.56M	15.24M	17.46M	125.80M	138.31M

Vaxart Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.42
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For VXRT, the sentiment is Positive. The current price of 0.42 is above the 20-day moving average (MA) of 0.40, below the 50-day MA of 0.42, and below the 200-day MA of 0.65, indicating a neutral trend. The MACD of <0.01 indicates Negative momentum. The RSI at 52.17 is Neutral, neither overbought nor oversold. The STOCH value of 48.36 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for VXRT.

Vaxart Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	52 Neutral	$5.04B	3.15	-44.58%	2.85%	16.08%	-0.27%
MGNX	50 Neutral	$97.79M	―	-60.25%	―	255.31%	-141.39%
VXRT	48 Neutral	$94.82M	―	-114.74%	―	433.43%	49.04%
ZNTL	46 Neutral	$85.46M	―	-59.45%	―	―	48.92%
SGMT	44 Neutral	$95.09M	―	-34.72%	―	-100.00%	-12.66%
IMUX	37 Underperform	$93.63M	―	-424.44%	―	―	51.02%
OBIO	36 Underperform	$108.04M	―	-179.12%	―	30.23%	-21.32%

Vaxart Corporate Events

Vaxart Receives BARDA Approval for Phase 2b Trial

On May 15, 2025, Vaxart, Inc. announced that it received approval from the Biomedical Advanced Research and Development Authority (BARDA) to begin dosing in the 10,000-participant portion of its Phase 2b clinical trial for its oral COVID-19 vaccine candidate. This trial, funded under Project NextGen, is a significant step in evaluating the efficacy and safety of Vaxart’s oral vaccine compared to existing mRNA vaccines, potentially impacting the company’s market positioning and offering a new approach to COVID-19 vaccination.

The most recent analyst rating on (VXRT) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on Vaxart stock, see the VXRT Stock Forecast page.

Spark’s Take on VXRT Stock

According to Spark, TipRanks’ AI Analyst, VXRT is a Neutral.

Vaxart’s overall score is driven by strong revenue growth and strategic initiatives, such as the proposed reverse stock split. However, profitability and cash flow issues, along with technical bearish momentum and potential NASDAQ delisting, weigh heavily on the stock. The company’s efforts to improve its financial position and operational efficiencies are crucial for future stability.

To see Spark’s full report on VXRT stock, click here.

Vaxart Appoints Jeroen Grasman as New CFO

On May 12, 2025, Phillip Lee announced his resignation as Chief Financial Officer of Vaxart, Inc., effective upon the appointment of a successor. His resignation was not due to any disagreements with the company, and he will assist with the transition until June 1, 2025. On May 13, 2025, Vaxart appointed Jeroen Grasman as the new Chief Financial Officer, effective May 19, 2025. Grasman, who has over 20 years of experience in biotech financial leadership, previously served as CFO at AltruBio and held significant roles at PACT Pharma and Genentech. His appointment is expected to support Vaxart’s advancement of its oral vaccine programs.

The most recent analyst rating on (VXRT) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on Vaxart stock, see the VXRT Stock Forecast page.

Spark’s Take on VXRT Stock

According to Spark, TipRanks’ AI Analyst, VXRT is a Neutral.

Vaxart’s overall score reflects strong revenue growth and progress in its norovirus vaccine program, which are positive factors. However, significant challenges in profitability and cash flow management, along with uncertainties in the COVID-19 program and bearish technical indicators, weigh heavily on the stock. The proposed reverse stock split may help stabilize the company’s market position, but current risks remain substantial.

To see Spark’s full report on VXRT stock, click here.

Vaxart Proposes Reverse Stock Split to Avoid Delisting

On May 12, 2025, Vaxart, Inc. issued a press release addressing frequently asked questions about a proposed reverse stock split, which will be voted on at the company’s Annual Meeting on May 21, 2025. The reverse stock split is intended to help Vaxart regain compliance with Nasdaq’s minimum bid price requirement and avoid delisting. The proposal is supported by leading proxy advisory firms, and Vaxart’s board of directors recommends stockholders vote in favor of it. The reverse stock split is seen as a strategic move to maintain Nasdaq listing, potentially increase market visibility, and enhance long-term value, which is crucial for the company’s future growth and financing opportunities.

The most recent analyst rating on (VXRT) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on Vaxart stock, see the VXRT Stock Forecast page.

Spark’s Take on VXRT Stock

According to Spark, TipRanks’ AI Analyst, VXRT is a Neutral.

Vaxart’s overall score is driven by strong revenue growth and progress in its norovirus vaccine program, providing a positive outlook. However, significant challenges in profitability, cash flow management, and uncertainties in the COVID-19 program weigh heavily on the stock. Technical indicators suggest bearish momentum, while valuation metrics highlight financial struggles. The company’s strategic initiatives and cash management efforts offer some hope for future stability, but current risks remain substantial.

To see Spark’s full report on VXRT stock, click here.

Vaxart Resumes COVID-19 Vaccine Trial After Government Lift

On May 5, 2025, Vaxart, Inc. announced significant progress in its vaccine programs, including the lifting of a government stop work order on April 24, 2025, which allows the continuation of a clinical trial for its COVID-19 vaccine candidate. The company is also advancing its norovirus program and is on track to report topline data by mid-2025. Vaxart is proposing a reverse stock split to be voted on at the upcoming annual meeting to avoid Nasdaq delisting, which could impact liquidity and funding opportunities. The company is implementing cost control measures to extend its cash runway into 2026 and is actively seeking non-dilutive funding to support its strategic initiatives.

Spark’s Take on VXRT Stock

According to Spark, TipRanks’ AI Analyst, VXRT is a Neutral.

Vaxart’s overall score is driven by strong revenue growth and progress in its norovirus vaccine program, providing a positive outlook. However, significant challenges in profitability, cash flow management, and uncertainties in the COVID-19 program weigh heavily on the stock. Technical indicators suggest bearish momentum, while valuation metrics highlight financial struggles. The company’s strategic initiatives and cash management efforts offer some hope for future stability, but current risks remain substantial.

To see Spark’s full report on VXRT stock, click here.